Using Microbiome to Predict Durvalumab Toxicity in Post-CCRT NSCLC Patients (Microdurva)
Jun Zhang, MD, PhD
Summary
This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treatment toxicity.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent * Participant is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up * Life expectancy ≥12 weeks * Males and females age ≥ 18 years * Allowable type and amount of prior therapy: Participants must have received two or more cycles of platinum-based chemotherapy (containing etoposide, vinblastine, vinore…
Locations (2)
- The University of Kansas Cancer Center, Westwood CampusKansas City, Kansas
- Rhode Island Hospital, Brown UniversityProvidence, Rhode Island